Rick Pauls

President & CEO

Rick Pauls was appointed our President and Chief Executive Officer in July 2009. Mr. Pauls has served as a member of our board of directors since April 2005 and as the Chairman of the Board from April 2008 to July 2014.

Before joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures, an early-stage life sciences venture capital fund, from February 2002 until January 2010. Mr. Pauls was an analyst for Centara Corporation, an early-stage venture capital fund, from January 2000 until January 2002. From June 1997 until November 1999, Mr. Pauls worked for General Motors Acceptation Corporation specializing in asset-backed securitization and structured finance. Additionally, Mr. Pauls has served on the board of directors of several public and private companies. Mr. Pauls received his B.A. in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.

Scott Kellen

Chief Financial Officer

Scott Kellen joined us in January 2018 as our Vice President of Finance and was appointed our Chief Financial Officer and Secretary in April 2018. 

Before joining DiaMedica, Mr. Kellen served as Vice President and Chief Financial Officer of Sun BioPharma, Inc., a publicly-traded clinical-stage drug development company, from October 2015 until April 2018.  From February 2010 to September 2015, Mr. Kellen served as Chief Financial Officer and Secretary of Kips Bay Medical, Inc., a publicly-traded medical device company. He became Chief Operating Officer of Kips Bay in March 2012.  From November 2007 to May 2009, Mr. Kellen served as Finance Director of Transoma Medical, Inc. From 2005 to October 2007, Mr. Kellen served as a Corporate Controller of ev3 Inc.  From March 2003 to April 2005, Mr. Kellen served as Senior Manager, Audit and Advisory Services of Deloitte & Touche, L.L.P.  Altogether, Mr. Kellen has spent more than 25 years in the life sciences industry, focusing on publicly traded early stage and growth companies. Mr. Kellen has a B.S. in Business Administration from the University of South Dakota and is a Certified Public Accountant (inactive).

Kirsten Gruis, M.D.

Chief Medical Officer

Dr. Kirsten Gruis was appointed our Chief Medical Officer effective as of January 5, 2022.

Prior to joining DiaMedica, Dr. Gruis served as Chief Medical Officer for Edgewise Therapeutics, Neuromuscular Franchise Head at Roche, Chief Medical Officer of Agilis Biotherapeutics, Inc. and a number of additional senior clinical development roles at companies including Wave Life Sciences Ltd., Idera Pharmaceutics, Inc., Alynylam Pharmaceuticals Inc. and Pfizer Inc. Prior to her time at Pfizer, Dr. Gruis was Associate Professor at SUNY Upstate and Assistant/Associate Professor at the University of Michigan, where she was a practicing neurologist for nearly ten years. Dr. Gruis earned her Medical Doctorate from the University of Iowa College of Medicine, has a Master of Science in Clinical Trial Design and Statistical Analysis from the University of Michigan, School of Public Health, and earned her Bachelor of Science in Microbiology from Iowa State University.

Dominic Cundari

Chief Commercial Officer

Dominic R. Cundari was appointed our Chief Commercial Officer effective as of February 1, 2022.

Mr. Cundari has over 30 years of pharmaceutical experience in various commercial roles in high growth markets. Prior to joining DiaMedica, Mr. Cundari served as an independent commercial strategy and development consultant for Genentech since February 2009. From January 1988 to January 2009, Mr. Cundari held a variety of sales and marketing management positions across multiple medical specialties at Genentech, a global biotechnology company. As Senior Director for the Vascular Franchise, Mr. Cundari was responsible for shaping commercial strategies, leading product launches in cardiology, pulmonary and neurology specialties and establishing strategic partnerships with telemedicine companies. Mr. Cundari holds both a Master of Science and Bachelor of Arts in Psychology from Villanova University.

Julie VanOrsdel Daves, MSHS, CCRP

Senior Vice President, Clinical Development Operations

Ms. Daves most recently served as a consultant to DiaMedica and as Vice President and Global Head, Clinical Operations at Sanifit, which was recently acquired by CSL in January 2022. Prior roles include leadership positions in clinical operations at Edgewise Therapeutics, miRagen Therapeutics, Chiltern, Array Biopharma, and BioCryst Pharmaceuticals. She has a broad range of experience from Phase 1a (first-in-human) through Phase 3 registrational studies, including renal, dermatology, arthritis, oncology, autoimmune and neuromuscular disease, and vaccine development. “This is an exciting time to join the DiaMedica team and to help complete the development of a novel treatment for acute ischemic stroke, a group of patients with truly significant unmet medical need,” she commented.

Ms. Daves is a certified clinical research professional and received her MSHS in Clinical Research Administration from The George Washington University School of Medicine and Health Sciences and BS in Zoology from North Carolina State University.

Edward G. Calamai, Ph.D.

Consulting Head of Manufacturing

Edward Calamai, Ph.D., was appointed our Consulting Head of Manufacturing in January 2020.

Dr. Calamai has over 30 years' experience with multiple products, including Sr. Vice President of Operations at Sensus Drug Development, where he was responsible for C.M.C. operations and compliance in support of the company's development and successful B.L.A. filing for a recombinant protein therapeutic.

Earlier in his career, he was Vice President of Operations at Seragen, Inc., R&D Manager at Baxter Travenol Laboratories, and also worked as an independent consultant in the area of biologics development, manufacturing, and regulatory compliance.

Dr. Calamai received his B.S. in Biology from Union College and a doctorate in Bacteriology and Immunology from the University of North Carolina in Chapel Hill. He was a postdoctoral fellow in cellular immunology in the Department of Pathology at Harvard Medical School.

Dr. Paolo Madeddu, MD

Senior Scientific Advisor and KLK1 Expert

Dr. Paolo Madeddu is an expert on the human protein KLK1 and the kallikrein-kinin-system, he has over 310 publications including over 55 related to KLK1, and internationally known for his research and publications. Dr. Madeddu obtained his MD degree in 1976 at the University of Sassari (Italy) and in 1980 became Specialist of Cardiology from the University of Sassari.   He worked as a Senior Consultant for the Internal Medicine Department and  Chief of the Regenerative Medicine Center in Osilo and Porto Conte Ricerche until 2005. He was then recruited by the University of Bristol, where he is currently a full professor in Cardiovascular Experimental Medicine.  He is Editor of Vascular Biology and Trends in Cardiovascular Regenerative Medicine, and associated editor of Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB). His research focuses  on new solutions to cardiovascular repair and rejuvenation, using gene therapy, protein therapy, and tissue engineering. He has received funding to this research from the Medical Research Council, the British Heart Foundation, Heart Research UK, Diabetes UK, JDFR, and the European Community.